middle.news
Can NeuroScientific’s StemSmart Transform Outcomes in Steroid-Refractory GVHD?
9:38am on Thursday 19th of June, 2025 AEST
•
Healthcare
Read Story
Can NeuroScientific’s StemSmart Transform Outcomes in Steroid-Refractory GVHD?
9:38am on Thursday 19th of June, 2025 AEST
Key Points
Positive Phase I trial results in adults with steroid-refractory acute and chronic GVHD
Compassionate use in children shows improved survival and symptom resolution
Phase II trial in newly diagnosed acute GVHD showed no added benefit
StemSmart acquisition from Isopogen WA Ltd progressing with conditions precedent
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuroscientific Biopharmaceuticals (ASX:NSB)
OPEN ARTICLE